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Abstract
Systematic reviews with economic components are important decision tools for 
stakeholders seeking to evaluate technologies, such as breast cancer screening (BCS) 
programs. This overview of systematic reviews explores the determinants of the 
cost‐effectiveness of BCS and assesses the quality of secondary evidence. The search 
identified 30 systematic reviews that reported on the determinants of the cost‐effec-
tiveness of BCS, including the costs of breast cancer and BCS. While the quality 
of the reviews varied widely, only four out of 30 papers were considered to be of 
a high quality. We did not identify publication bias in the original evidence on the 
cost‐effectiveness of mammography screening; however, we highlight a need for im-
proved clarity in both reporting and data verification. The reviews consisted mainly 
of studies from high‐income countries. Breast cancer costs varied widely among the 
studies. Factors leading to higher costs included: time (diagnosis and last months 
before death), later stage or metastases, recurrence of the disease, age below 64 years 
and type of follow‐up (more intensive or more specialized). Overall, screening with 
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1 |  INTRODUCTION
Systematic reviews are widely accepted as a tool to increase 
the flow of scientific information.1 A dramatic increase in 
primary health economic studies has led to a consequent pro-
liferation of systematic reviews synthesizing this economic 
evidence. These reviews may serve as a decision tool for 
stakeholders by evaluating the methodological rigor of the 
available economic evidence, defining principal cost drivers, 
summarizing variability in economic outcomes, or identify-
ing the scientific gaps requiring further exploration. As such, 
these summaries are especially useful for the prospective 
evaluation of large‐scale programs requiring significant im-
plementation and maintenance funding, such as breast cancer 
screening (BCS).
Breast cancer is the leading cause of death from cancer 
among women worldwide.2 Large randomized controlled tri-
als and cohort studies, mainly conducted in North America 
and European countries, indicate that breast cancer mortality 
can be reduced by implementing screening mammography 
among women aged 50‐59 years.3 While there are multiple 
discussions on the benefit to harm ratio of screening mam-
mography, it is generally considered as favorable by most of 
the systematic reviews synthesizing outcomes from random-
ized clinical trials and observational or population studies.3 
Thus, guidelines from international cancer networks—in-
cluding the European Union Council Recommendation on 
Cancer Screening—recommend mammography screening 
for this segment of the population.4-6 Scarce capacity lim-
its application of these recommendations in low‐income 
settings, where clinical breast examination (CBE), breast 
self‐examination (BSE), and screening ultrasonography may 
be recommended by local guidelines either as individual or 
supplementary interventions.7-15
To define if a screening program provides value for 
money, cost‐effectiveness analysis is used. Cost‐effective-
ness analysis is a comparative method, which combines 
relative costs and outcomes of different interventions 
into a single metric—the cost‐effectiveness ratio (CER) 
or incremental cost‐effectiveness ratio (ICER). The most 
frequently used outcome measures in cost‐effectiveness 
assessment of chronic illnesses, such as breast cancer, are 
quality‐adjusted life years (QALYs, a measure of disease 
burden including the quality and duration of life) or disabil-
ity‐adjusted life years (DALYs, a measure of disease burden 
including the disability and years of life lost). Depending on 
the viewpoint of the stakeholders, cost‐effectiveness analy-
sis can consider a variety of costs, such as direct costs (costs 
of screening, treatment, follow‐up, etc) and indirect costs 
(productivity loss for patient and caregiver). While multi-
ple approaches to interpreting cost‐effectiveness exist,16 
new technologies, in general, are considered to have a fa-
vorable CER if it is lower than the threshold established in 
the country or if it is less than average per capita income 
per DALY.17
The cost‐effectiveness of BCS programs is dependent 
on economic and healthcare system settings as well as the 
methodological approaches toward evaluation. The factors 
that would affect the cost‐effectiveness of BCS in popula-
tions would include patient characteristics and epidemio-
logical factors, screening accuracy, coverage and screening 
uptake, access to diagnosis and treatment, and costs of both 
breast cancer and implementation of screening programs. 
While multiple reviews on economic evaluations around 
BCS have been published over the last decades, no research 
to our knowledge has summarized these reviews’ findings 
on the cost‐effectiveness of the screening programs. In the 
current overview, we aim to explore determinants of the 
cost‐effectiveness of BCS according to existing systematic 
reviews.
2 |  METHODS
The design of this study was reported in the published pro-
tocol, available open‐access online,18 and registered with the 
International Prospective Register of Systematic Reviews 
(PROSPERO), registration number CRD42016050765. 
mammography was considered cost‐effective in the age range 50‐69 years in Western 
European and Northern American countries but not for older or younger women. Its 
cost‐effectiveness was questionable for low‐income settings and Asia. Mammography 
screening was more cost‐effective with biennial screening compared to annual screen-
ing and single reading using computer‐aided detection vs double reading. No infor-
mation on the cost‐effectiveness of ultrasonography was found, and there is much 
uncertainty on the cost‐effectiveness of CBE because of methodological limitations.
K E Y W O R D S
breast cancer screening, cost‐effectiveness, costs, review
   | 3MANDRIK ET AL
We systematically searched PubMed via Medline, Scopus, 
Embase, and Cochrane databases in August 2016 and con-
ducted updates and searches for gray literature in April 2018 
and again in August 2018 (Appendix 1). As a deviation from 
the protocol, we included two systematic reviews that con-
ducted the search in only one country—the USA, since they 
presented the most comprehensive data on the costs of breast 
cancer.
The quality of the included reviews was assessed by using 
the Assessing the Methodological Quality of Systematic 
Reviews (AMSTAR) checklist19 relevant for systematic re-
views of cost and cost‐effectiveness outcomes and an ad-
ditional question on transferability of the findings. We 
considered that the conclusions of the reviews were trans-
ferable to comparable jurisdictions, if the reviews reported 
low variability and uncertainty of the results, and consid-
ered the quality of original evidence as high or sufficient 
(Appendix 2 presents the decision framework). Furthermore, 
we narratively summarized the outcomes of the reviews that 
had a quality score of three or higher, considering the reviews 
with lower scores as nonsystematic. To explore the impact of 
the funding of the study, specialization of the department of 
the corresponding author, geographic focus of the review’s 
search, year of the search, and the outcomes reported (cost or 
cost‐effectiveness), we used a stepwise multiple regression.
To analyze publication bias in the original evidence, we 
assessed the distribution of ICER per outcomes expressed in 
life years gained, QALYs, or DALYs in the reviews report-
ing on the cost‐effectiveness of screening mammography 
comparing to no screening. Similar to Bell et al (2006),20 
we considered that publication bias exists if the published 
ratios cluster around the countries’ decision thresholds. 
Countries’ acceptability thresholds were expressed from 
one to three times the gross domestic product (GDP) per 
capita21 in the year prior to the publication year of the orig-
inal evidence.
F I G U R E  1  PRISMA 2009 Flow diagram
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3 |  RESULTS
We identified 7768 abstracts through our database search, 
with 451 more gray literature sources reviewed (Figure 1). 
The interrater reliability between the two reviewers for deci-
sions on full‐text inclusion was 92% (Cohen’s kappa = 0.7; 
substantial agreement). The excluded reviews and reasons 
for the exclusion are outlined in Appendix 3.
Out of 30 included reviews, 14 reported data on the costs 
of breast cancer and 16 on the costs of BCS (the character-
istics of the included studies are indicated in Appendix 4). 
Most reviews did not limit their search to a particular set-
ting; some, however, aimed to identify studies comparable 
to either the UK,22,23 North America,24-29 Sweden,30 Iran,31 
Asia,32 or high33‐ or low34‐income countries. Most stud-
ies included in the reviews were conducted in high‐income 
settings (Appendix 4), with little original research available 
for low‐and middle‐income countries. In particular, these 
reviews related to the cost‐effectiveness of BCS in Brazil, 
India, Mexico, Turkey, Ghana, and Egypt and productivity 
loss in Brazil, Peru, and Pakistan. In total, only two included 
reviews reported low variability and uncertainty in the syn-
thesized results; the results of these reviews were considered 
applicable to high‐income countries.35,36 The results of the 
studies are presented according to the described framework 
(Figure 2), reporting first the breast cancer costs and then the 
cost and cost‐effectiveness of BCS.
3.1 | The determinants of breast 
cancer costs
From a macroperspective point of view, almost half of breast 
cancer costs are related to medication costs, with nonmedi-
cal costs and productivity costs taking a quarter each.37,38 
According to Foster et al,39 the financial impact of breast can-
cer (assessed on a macrolevel in the USA and Australia) was 
related to high trastuzumab costs and discard on its dispended 
prescriptions. The results from the five reviews concluded 
that direct medical breast cancer costs on a microlevel in-
creased in the initial year after diagnosis and the last months 
before death (for out‐of‐pocket costs—the last 12 months of 
life40), later stage or metastatic breast cancer patients, receiv-
ing adjuvant chemotherapy, recurrence of the disease than 
the initial cancer, and age younger than 64 years (vs an older 
age).37,39-41
Six reviews, mainly based on the same original evidence, 
reported resource use or costs of breast cancer follow‐up 
(Appendix 5).22,30,35,42-44 The highest rate of resource use was 
for follow‐up visits and follow‐up mammography,44 while the 
frequency of visits decreased twice in the initial 4 years after 
F I G U R E  2  The conceptual framework of the review
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treatment.43 The follow‐up costs could be affected by poor 
continuity of the doctor‐patient relationship, with patients 
seeing multiple doctors during the follow‐up and doing al-
most twice the recommended number of visits.43 The cost 
of intensive follow‐up was 2‐5 times higher than minimal 
follow‐up while not having an impact on survival 22,35,42,43; 
the cost of follow‐up was lower if it was in the primary vs 
secondary setting,22,30,35,43 nurse‐led,44 or nurse‐led phone 
follow‐up combined with an educational program,30 or phone 
or through mobile application technologies.22,35 Even though 
no impact on clinical outcomes was recorded with follow‐up 
in the primary setting, patients’ satisfaction was much higher 
with specialist follow‐up.22,30
Seven reviews concluded that breast cancer has a signif-
icant impact on the productivity of women in all the coun-
tries considered,24,36,38-41,45 affecting the unemployment rate 
of breast cancer survivors and causing financial hardship for 
families of cancer patients.40 The unemployment rate varied 
widely among the studies and the countries (from 20%‐55% 
at 3‐24 months in Germany, the USA, and France to 12%‐43% 
after 6‐9 years in the USA, Sweden, Canada, and Germany). 
Because of heterogeneity in methods, background unemploy-
ment rates, and population characteristics, it is impossible 
to conclude on any real differences in the geographic set-
tings.24,36,38,40,45 Similarly, the average return to work varied 
widely among the countries, for instance, being three times 
longer in the Netherlands than in Sweden.38
3.2 | Determinants of breast cancer 
screening costs and cost‐effectiveness
Only one narrative review reported the costs of organized 
invitations, with the cost of follow‐up reminder being 3‐9 
times higher than the cost of initial invitation.25 In general, 
mammography was considered to be cost‐effective to screen 
50‐ to 69‐year‐old women in three reviews reporting studies 
from Western European and North American countries,31,32 
although questionable for low‐income settings34 and Asian 
regions (that was argued by differences in incidence rates and 
density of breast tissues)32 (Table 1). BCS costs were lower 
with biennial mammography compared with annual mam-
mography in the review of Health Quality Ontario (2016)29; 
consequently, biennial mammography screening was consid-
ered to be the most cost‐effective option in the review by 
Rashidian et al (2013), although the range of cost per life year 
gained was the lowest for triennial screening.31 Incremental 
cost per life year gained of continuing mammography screen-
ing for women above 65 years of age compared with stopping 
regular screening at that age was 34000‐88000 USD (2002). 
Although it could possibly be lower if screening decision 
would be based on women's health state.27 The cost‐effec-
tiveness of screening of women younger than 50 years of age 
had a range within the recommendations of the World Health 
Organization of three times GDP per capita (14000‐26200 
USD per life year gained in the USA in 1994 and 45000 USD 
per QALY gained in the UK, 2010). However, the authors of 
this systematic review did not consider BCS for this group of 
women cost‐effective.31
Several reviews assessed the impact of different organi-
zational aspects on the cost‐effectiveness of screening mam-
mography. The review of Baron (2010) identified more than a 
50% increase in cost of invitation for those women requiring 
a follow‐up reminder to come for screening.33 The review by 
Ho et al (2002) identified significantly higher costs of cap-
ital equipment for digital mammography compared to film 
mammography, although the former reduced the number of 
examination repeats (1.5%‐6%) and decreased examination 
time by around 5 minutes.28 Double reading was considered 
not to be a cost‐effective intervention in comparison to single 
reading with computer‐aided detection in the review of Posso 
et al (2017).47 Another review estimated the costs of person-
alizing screening intervals considering an individual’s cancer 
risk, concluding higher cost (2000‐2500 USD, 2014) for a 
higher risk population.42
While mammography was a target intervention in most 
of the reviews, three publications reported BCS costs for the 
other screening approaches (Table 1). Zelle et al (2013) re-
ported that CBE can be a cost‐effective screening method 
for some low‐income settings (India, Ghana, and Egypt).34 
Baxter et al (2001) estimated the range of costs (574‐848 
USD) necessary to educate one woman to regularly and com-
petently practice breast self‐examination.26 The report by 
Health Quality Ontario targeted to identify the cost‐effective-
ness of adjunct ultrasonography including women of general 
risk; no study for average risk women reporting the cost‐ef-
fectiveness of combined screening was identified though.29
3.3 | Quality and bias in evidence on cost‐
effectiveness of breast cancer screening
The quality of the included reviews ranged from 1 to 7 (from 
a maximum possible of 9 in AMSTAR), of which 25 reviews 
had a quality score of three or above and were included in the 
data synthesis (Table 2).
From the relevant AMSTAR criteria, most systematic re-
views had a comprehensive literature search (81%) and re-
ported study characteristics (84%). Only three reviews (10%) 
reported the conflict of interest for included original research, 
and only five (17%) reported having a protocol (Figure 3). A 
stepwise multiple regression model evaluated the impact of 
factors on the AMSTAR score. The final regression model 
excluded factors such as funding of the study and the spe-
cialization of the department of the corresponding author, 
including a geographic focus of the review’s search (world 
vs country or region‐specific, P  <  .05), year of the search 
(P < .1), and reporting cost‐effectiveness parameters vs only 
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T A B L E  1  Breast cancer screening cost and cost‐effectiveness outcomes
Author, year Searched outcomes Reported outcomes
Reported conclusions on cost‐effective-
ness or heterogeneity
Wagner, 
199825
Costs of invitation for MM (USA, 
Australia)
(a) Unit costs
(b) Cost per woman screened
(c) Cost of follow‐up reminders
(a) 0.45‐2.78 USD
(b) 0.96‐5.88 USD
(c) 3.25‐26.81 USD
More research is needed to assess the 
cost‐effectiveness of patient reminders
Baxter, 
200126
Cost of BSE education programs per 
competent frequent self‐examiner 
added
574‐848 USD (USA, 1993) No conclusion
Dinnes, 
200123
(a) Incremental cost per additional 
cancer detected (UK, France, USA)
(a) 1162‐2221 GBP, 21838FF, 25523 
USD
Cost‐effectiveness estimates have been 
produced which lie within the range 
of what may be considered to be 
“cost‐effective”.
Ho, 200228 (a) Resource use with DM vs FSM
(1) Examination time
(2) Repeat examinations
(b) Incremental capital equipment 
(1995‐2001, USD)
(c) Annual operating costs
(a) Resource use with DM vs FSM
(1) < by 5.3‐6.3 min
(2) <1.48%‐6%
(b) 50000‐284000 USD
(c) Not consistent
DM equipment is more expensive than 
FSM, but has reduced time and reduced 
repeats
Mandelblatt, 
200327
Cost and cost‐effectiveness extending 
BCS above 65 y
(a) Diagnosis costs (2002, USD)
(b) Treatment costs (2002, USD)
(c) Incremental costs per life year 
saved
(a) 451‐2520 USD
(b) 7991 (surgery only)‐45220 USD
66‐194 USD
(c) 34000‐88000 USD
Health state of women (risk of complica-
tions), age
Baron, 201033 Cost of reminders per additional 
MM for those appearing on time vs 
requiring additional prompting
75 USD vs 118 USD Patients’ punctuality impacts the costs
Baron, 200849 Economic efficiency of reducing 
structural barriers in increasing 
breast cancer screening
No studies were found Not applicable
Rashidian, 
201331
Cost‐effectiveness of MM screening
(a) Cost per life year, mixed age
(b) CER for 50‐ to 70‐year‐old
(1) Cost per LYG, biennial
(2) Cost per LYG, annual
(3) Cost per LYG, triennial
(4) Cost per QALY (all intervals)
(5) Cost per DALY (1 study)
(6) Cost per cancer detected
(c) CER for women over 70
(1) Cost per LYG, annual
(2) Cost per QALY
(d) CER for women younger 50
(1) Cost per LYG
(2) Cost per QALY
(a) 1634 USD ( India)‐64400 USD 
(Australia)
(b) CER for 50‐ to 70‐year‐old
(1) 2685 USD (UK, 1993)‐21400 USD 
(USA, 1997)
(2) 15500 USD (USA, 1994)‐45700 
(USA, 1997)
(3) 4343USD (UK, 1998)—13081 
(Australia, 1993)
(4) 9801 USD (Slovenia, 2008‐46500 
(USA, 1997)
(5) 75 (Africa)—915 USD (North 
America, 2006)
(6) 8424USD (Spain, 1996)‐17202 USD 
(Norway, 1999)
(c) BCS MM for women over 70
(1) 35000 USD (USA, 1994)
(2) 8119‐27751 USD (other review)
(d) CER for women younger 50
(1) 14000−26200 USD (USA, 1994)
(2) 44692 (UK, 2010)
Biennial screening test for those aged 
50‐70 y seems to be the most cost‐effec-
tive option. Screening those aged less 
than 50 is not recommended.
(Continues)
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Author, year Searched outcomes Reported outcomes
Reported conclusions on cost‐effective-
ness or heterogeneity
Yoo, 201332 Cost‐effectiveness of MM BCS in 
Western and Asian countries
(a) Cost per LYG or QALY (Asian 
countries)
(b) Cost per LYG or QALY (Western 
Europe)
(c) Logged CE/per capita GDP ratio 
predictions
(a) 3308 USD (India, 2008) −90771 USD 
(China, 2007)
(b) 3235 USD (NL, 1991)‐48884 USD 
(USA, 2011)
(c) −0.69 (Spain, 2011)‐1.69 (China, 
2007)
Incidence rate and racial characteris-
tics (breast tissue density) affect the 
outcome. Cost‐effective cutoff point of 
breast cancer incidence rate was 45.04; 
it exactly divided countries into Western 
and Asian countries.
Zelle, 201334 Cost‐effectiveness of BCS 
alternatives
(a) MM
(b) CBE
(c) Other BCS considered 
cost‐effective
(a) Cost‐effective: sub‐Saharan Africa 
and South East Asia (2248‐4596 USD/
DALY), Mexico (22000 ID/DALY), 
Poland, Turkey (2006, 2011), not ra-
tional—Iran, not cost‐effective—Ghana.
(b) Cost‐effective: India, Ghana (1299 
USD/DALY), Egypt
(c) Tactile imaging (incremental costs not 
reported)
BCS may be economically
attractive in LMICs—yet there is little 
evidence to provide specific recommen-
dations on screening by
MM vs CBE, the frequency of screening, 
or the target population.
Koleva‐
Kolarova, 
201548
Cost per outcome (undefined) in 
nonconverted currency
1800 GBP (UK, 1993) −715000 EUR 
(Spain, 2011)
Most reported screening regimens 
fulfilled the WHO criteria with the 
exception of some very intensive USA, 
Spanish and Indian scenarios.
Li, 201550 (a) Cost per LYG with MM screening 
(India 2008, Brazil 2012)
(b) Cost‐effectiveness of CBE vs MM 
(India)
(c) CAD vs double reading (2015)
(a) 3468 USD, 6516 USD
(b) Cost‐effective (no ICER reported)
(c) Cost‐effective (no ICER reported)
Results from high‐income countries are 
not applicable to low‐income settings 
and should be accessed on individual 
basis
Abdel‐Aleem, 
201651
Total costs per screened patient 
(USA, 2009):
(a) Stationary full digital screening 
unit
(b) Mobile full digital screening unit
(c) Mobile film screening unit
(a) 41 USD
(b) 102 USD
(c) 86 USD
The cost of screening per woman may 
be higher for mobile clinics than for 
permanent clinics (low certainty)
Health 
Quality 
Ontario, 
201629
BCS costs per 1000 women (1 study):
(a) Biennial in 50‐74 y.o.
(1) MM
(2) MM + US, dense breast, (+incre-
mental LYG and QALY)
(3) MM + US, heterogeneously or 
dense breast
(b) Annual 40‐74
(1) MM
(2) MM + US dense breast (+incre-
mental LYG and QALY)
(3) MM + US, heterogeneously or 
dense breast
(a) Biennial in 50‐74 y.o.
(1) 3.02 mln USD
(2) 3.08 mln USD (1.2 LYG, 1.1 QALY)
(3) 3.39 mln USD (2.1 LYG, 1.7 QALY)
(b) Annual 40‐74
(1) 5.15 mln USD
(2) 5.42 mln USD (3.6 LYG, 3.1 QALY)
(3) 6.58 mln USD (3.7 LYG, 3.0 QALY)
No studies on MM + US to screen aver-
age‐risk women
T A B L E  1  (Continued)
(Continues)
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cost parameters (P = .174). The model predicted 47% of vari-
ance in the AMSTAR score with residual standard error of 
1.133 on 23 degrees of freedom.
Four systematic reviews on the cost‐effectiveness of BCS 
in comparison to no screening reported the outcomes from 67 
studies in total (Appendix 6). While most of the inclusion cri-
teria were similar among the three reviews, 13%‐60% of the 
original articles were not included in one or another review 
when expected. Among those studies included in two or more 
reviews, 10 out of 22 (45%) had different ranges for reported 
ICERs; these differences in the reporting were not related to a 
particular trend of cost‐effectiveness estimates. Two of these 
four systematic reviews were used to assess the risk of publi-
cation bias. The other two were excluded due to poor reporting 
of programs and outcomes. We did not identify a risk of pub-
lication bias in the original studies with differences between 
GDP and ICER varying widely depending on the country of 
evaluation, screening interval, and age groups (Appendix 6).
4 |  DISCUSSION
This systematic review assessed the determinants of the cost‐
effectiveness of BCS as well as the methods and quality of 30 
included systematic reviews.
4.1 | Determinants of the cost‐
effectiveness of mammography screening
The determinants of the cost‐effectiveness of BCS were split 
into two stages indicated in the conceptual framework, the 
screening costs, and the breast cancer costs, with the later 
including the costs related to the diagnosis, treatment, and 
follow‐up. Breast cancer costs were affected by the disease 
characteristics (eg, stage and incidence), patients’ charac-
teristics (eg, age), health provider characteristics (eg, nurse 
vs general practitioner follow‐up), and health system char-
acteristics (eg, discard of dispensed prescriptions and lack 
of societal insurance).22,37,39-42,47,30,35,43-45 There was not 
enough evidence to evaluate how the impact of these fac-
tors on breast cancer cost would differ between high‐ and 
low‐income countries. While low‐income countries have less 
financial means and lower breast cancer expenses, wastage 
and improper resource allocation also contribute to the ineffi-
ciency of the healthcare systems in these jurisdictions.52 With 
high breast cancer mortality rates in countries with limited 
resources,52,53 one may speculate that improvement of the ef-
ficiency in healthcare systems,52 including cancer treatment 
in national health insurance coverage,54 gaining capacity, and 
setting early cancer detection programs,55 should go prior to 
BCS implementation.
The cost and cost‐effectiveness outcomes related to 
screening were influenced by population characteristics (eg, 
age, personal cancer risk, and breast tissue density), screening 
organization (eg, screening interval, prompting, mammogra-
phy type, and number of readers), and disease characteristics 
(eg, breast cancer incidence).27,31-33,47 Screening mammog-
raphy was the most reported intervention in the reviews of 
the cost‐effectiveness of BCS and was generally accepted as 
cost‐effective for 50‐ to 69‐year‐old women in high‐income 
settings but not in low‐income settings or in Asian popula-
tions. What undervalues the economic assessments of BCS 
Author, year Searched outcomes Reported outcomes
Reported conclusions on cost‐effective-
ness or heterogeneity
Arnold, 
201742
Personalized screening (screening 
interval is dependent on personal 
risk), general population
(a) cost/QALY (2014)
(b) Difference between lower and 
higher risk women (2014)
(c) Cost of screening, low risk
(d) Cost of screening, average risk
(e) Cost of screening, moderate risk
(a) Dominant‐246000 USD (USA)
(b) 2000‐2500 USD
(c) 247‐2840USD
(d) 377‐1656USD
(e) 1248‐5304USD
Lower risk women have lower screening 
cots
Posso, 201747 (a) Incremental cost of double vs 
single reading (2005, PPP)
(b) Cost per LYG of single read-
ing + CAD vs double reading (2015)
(c) Cost per cancer detected of double 
reading vs single (2015)
(a) 25.7 USD‐271886 USD
(b) 2951USD
(c) 24717 USD
Double reading was not cost‐effective in 
comparison to single reading or single 
reading + CAD
Abbreviation: BCS, breast cancer screening; BSE, breast self‐examination; CAD, Computer‐Aided Detection; CER, cost‐effectiveness ratio; CPI, consumer price 
index for medical care; DALY, disability adjusted life years; DM, digital mammography; EUR, Euro; FSM, film screening mammography; GBP, Great British Pound; 
GDP, gross domestic product; ID, international dollars; LYG, life years gained; MM, mammography; NL, the Netherlands; PPP, Purchasing power‐parity; UK, united 
kingdom; US, ultrasonography; USD, United States dollar; QALY, quality adjusted life years; y.o., years old.
T A B L E  1  (Continued)
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T A B L E  2  Assessment of quality of included systematic reviews (Score 9 is the maximum)
First author, year Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q11 QT S
a
Wagner, 1998 25 2
Baxter, 2001 26 4
Dinnes, 200123 2
Ho, 2002 28 4
Mandelblatt, 2003 27 3
Collins, 200444 4
Baron, 200849 4
De Boer, 200936 5
Campbell, 200941 3
Lewis, 200945 6
Baron, 201033 3
Foster, 201139 3
van Hezewijk, 201243 3
Rashidian, 201331 4
Yoo, 201332 5
Zelle, 201334 4
Jaspers, 201440 4
Koleva‐Kolarova, 201548 4
Li, 201550 1
Meregaglia, 201535 5
Muka, 201537 4
Chaker, 201538 4
Abdel‐Aleem, 201651 7
Browall, 201630 3
(Continues)
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among younger and older women is that the evidence on the 
benefit/harm ratio of screening mammography in these pop-
ulations is inconclusive or limited.3 Nevertheless, the conclu-
sions on the cost‐effectiveness of screening mammography 
among women younger than 50 years old or older than 69 
years old could vary from those presented if other clinical 
outcomes were selected, since the incidence of breast can-
cer (and so advanced cases prevented) was higher among the 
older population (while the younger population accumulated 
more life years gained) or if the individual‐based screening 
approach would be evaluated.
The results of this review have a dual‐fold impact. Firstly, 
policy makers should take the factors listed above seriously, 
especially when new screening programs are designed. These 
factors are prerequisites for an optimal implementation of a 
cost‐effective screening program, even though the BCS of 
50‐ to 69 year‐old‐women is considered to be, in general, a 
cost‐effective intervention. A comprehensive cost‐effective-
ness evaluation of BCS with long‐term forecasted outcomes 
supported by the evidence from local pilots would support 
efficient program design and functioning.
Secondly, the differences in healthcare systems, health pro-
viders, and populations as well as breast cancer costs and their 
determinants should be considered in estimations of the trans-
ferability of findings on the cost‐effectiveness of BCS. The 
transferability approaches suggest that, at a minimum, prac-
tice patterns and unit costs from the jurisdiction of interest 
should be considered.56 In relation to prevention approaches, 
First author, year Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q11 QT S
a
Health Quality Ontario, 
201629
6
Arnold, 201742 6
Kamal, 201724 4
Posso, 201747 7
Sun, 201646 2
Barbieri, 201822 2
aThe total score is based on nine questions from the AMSTAR instrument. AMSTAR stands for A Measurement Tool to Assess systematic Reviews (https ://amstar.
ca).19 The AMSTAR checklist consists of 11 questions, with “yes” answers being counted with a score of one. AMSTAR characterizes quality at three levels: 8 to 11, 
high quality; 4 to 7, medium quality; and 0 to 3, low quality. Q1: “a priori” design; Q2: duplicate selection and extraction; Q3: comprehensive search; Q4: gray litera-
ture; Q5: reporting excluded and included studies; Q6: reporting studies’ characteristics; Q7: quality assessment; Q8: quality consideration; Q9: data synthesis; Q10: 
publication bias; Q11: conflict of interest; and QT: question on transferability. Please refer to Appendix 2 for the decision process. 
T A B L E  2  (Continued)
F I G U R E  3  Quality of the included 
systematic reviews
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not only the unit costs of the preventive intervention but also 
cost of the disease itself, would define transferability of cost‐
effectiveness estimates. Considering the long‐term effect of 
the indirect costs related to breast cancer as well as high het-
erogeneity in cost outcomes by patient characteristics, an in-
dividual‐level approach to model‐based economic evaluations 
would be more relevant to capture the long‐term impact of 
the disease on both the well‐being and patient‐related costs. 
Finally, the model parametrization approaches, in particular, 
calibration, will also affect the transferability of the cost‐ef-
fectiveness results. Calibration is a strategy for quantifying 
unobserved model parameters to mimic the observed histor-
ical data. Considering that the natural history of the disease 
frequently includes undetected states and so transitions, cal-
ibration is frequently applied in health economic modeling 
approaches. The source of target data to fit in the calibration 
(whether it is a global, regional, or local source of statistics), 
would anchor the results narrowly (to one specific program or 
environment) or broadly (to multiple settings).
4.2 | Other breast cancer 
screening modalities
Besides mammography, limited (for BSE and CBE) to no 
(for ultrasonography) information was reported on other 
screening modalities. Even though CBE and BSE are gener-
ally perceived as low‐investment approaches, they also re-
quire launch and maintenance costs related to the education 
and enrollment of women. Costs required for BSE education 
were reported in one review,26 and the cost‐effectiveness of 
CBE in another review, suggesting it to be a cost‐effective 
method for some low‐income settings (India, Ghana, and 
Egypt).34 The secondary sources are consistent in presenting 
sufficient evidence of no benefits but harms of BSE and on 
insufficient evidence of a mortality decrease in breast cancer 
with regular CBE.3 By this, models assessing the benefits of 
CBE would rely on intermediary outcomes—stage shifting 
of breast cancer—rather than real‐life data on mortality de-
crease, which underpins assessments of the cost‐effective-
ness of this intervention.
4.3 | Quality and bias in the evidence
While the quality of the reviews varied widely, only four of 
them were considered to be of a high quality (scored 6 or 
above on AMSTAR). Meanwhile, there was no clear relation 
between the quality of the included systematic reviews and 
their conclusions. Reviews having a wide geographic focus 
(world rather than targeting a certain country or region) and 
more recent search tend to have higher AMSTAR scores. Our 
more in‐depth analysis of reporting from four systematic re-
views has shown potential risk of search, selection, extrac-
tion, and reporting mistakes in the reviews rather than biases 
in these studies. Similarly, we did not identify publication bi-
ases in the original evidence. We consider that cost‐effective-
ness analyses of public preventive programs, such as BCS, 
may be at less risk of publication bias than pharmaceutical 
treatments. To improve the quality, reliability, and applica-
bility of systematic reviews, the reviewers should refer to the 
developed guidelines in their methods, provide more trans-
parent reporting of programs and outcomes, and consider the 
transferability of their findings.
4.4 | Research and information gaps
Our overview shows that more original trial‐based economic 
evaluations along with pilots of CBE and ultrasonography 
with evidence on clinical and economic benefits are required. 
In addition, more high‐quality field‐based studies and reviews 
on the cost‐effectiveness of mammography screening in low‐ 
and middle‐income countries as well as the cost‐effectiveness 
of mammography screening among older women are also re-
quired. Economic evaluations of BCS considering personal risk 
stratification would be an asset for health decision‐making. A 
better understanding of costs related to informal care and indi-
rect screening program costs would help to decide how these 
finances should be considered in economic analyses of breast 
cancer. Standard and better structured collection and reporting 
of costs would improve comparability among the studies. The 
risk of bias tool designed for the reviews reporting cost out-
comes would help to interpret the results of these studies and 
potentially simplify their use in healthcare decision making.
4.5 | Limitation
With the large scope of the searched literature, it is possible 
that we missed some of the important information, despite the 
comprehensive approach applied in this review. We also devi-
ated from the protocol, including two reviews on which agree-
ment between two raters was not reached. The AMSTAR tool 
was not fully applicable to assess the quality of the systematic 
reviews with cost and cost‐effectiveness outcomes. In addition, 
the applied transferability metric was not validated, and the use 
of a standard validated tool specific for systematic reviews of 
economic evaluations would be a preferable approach.
5 |  CONCLUSIONS
Screening mammography may be a potentially cost‐effective 
intervention, although how cost‐effective it is would depend on 
population characteristics (such as incidence and starting age 
for screening) and screening organization (screening interval 
and screening approach) as well as the direct and indirect costs 
of breast cancer and their determinants. No information on the 
determinants for the cost‐effectiveness of ultrasonography was 
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retrieved, and the cost‐effectiveness of CBE is not certain be-
cause of methodological limitations. No risk of publication bias 
in the original evidence was identified, although high variabil-
ity and uncertainty in both the original and secondary evidence 
may limit the value of these reviews.
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